Juliana Liu Argues Medicines Should Stay Out of the US-China Tech War

What changed

Juliana Liu argues that novel medicines should not be treated like semiconductors or electric vehicles in US-China technology policy. Her point is that medicine is not automatically a zero-sum contest in which one country’s gain must be another’s loss.

Why it matters

That distinction puts the policy question in sharper focus. Treating novel medicines as strategic technology could make cooperation harder; treating them as a separate category leaves room to judge them on their medical value rather than folding them into every technology dispute.

The argument is still a policy position, not a reported change in law, regulation, company strategy or government action. Its importance lies in the choice it presents: whether US-China competition should apply the same logic to medicines that it applies to semiconductors and electric vehicles.